Skip to main content
OpenTrials
Completed

NCT Number: NCT06962501

Acute Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity

The primary objectives of this pilot study are to test if a single dose of an oral ketone monoester supplement will increase blood flow and connectivity in the brain in adults with subjective cognitive decline (SCD) or mild cognitive impairment (MCI).

The main questions it aims to answer are:

Does a single dose of an oral ketone supplement increase global cerebral blood flow (CBF)?

Does a single dose of an oral ketone supplement improve resting-state functional connectivity in the Default Mode Network (DMN)?

Does the increase in CBF positively correlate with improved functional connectivity in the DMN?

Participants will:

* Attend one 2-hour session, which includes: * Neurocognitive assessment * MRI Scans (two, each 15 Minutes) * Capillary blood ketone level measurements * Hemodynamic assessment (blood pressure, heart rate)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

55 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of Basel

Basel, Canton of Basel-City, 4031, Switzerland

About this study

In this non-randomized, single-arm study participants will undergo a baseline MRI scan to assess functional connectivity in the DMN and resting CBF without ketone supplementation. Participants will then consume 0.3 g/kg body weight of a ketone monoester supplement (∆G Tactical) and then rest for 70 minutes. Participants will then undergo a second MRI scan to evaluate changes in functional connectivity and CBF, with capillary β-OHB and blood pressure measured before and after each scan. The entire experimental visit, including scans and assessments, will last up to 2 hours.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 55 years or older
  • Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI)

SCD CRITERIA:

  • Self-experienced, persistent decline of cognitive abilities within the last 5 years in relation to a previously normal status
  • Normal results on demographically adjusted standardized cognitive tests
  • Accompanied by concerns associated with SCD and a feeling of worse performance than others in the same age group
  • Decline must not be related to a specific event or explained by a specific disease, medical disorder, medication, or substance abuse

MCI CRITERIA

  • Fulfils criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5):
  • Demographically adjusted performance between -1 and -2 SD below average in one or more cognitive domains on standardized cognitive tests
  • Accompanied by concern from the individual, a knowledgeable informant, or clinician indicating mild cognitive decline
  • Capacity for independent daily activities is maintained

Exclusion criteria

  • Clinical diagnoses of psychiatric disorders (e.g., anxiety disorders, depression)
  • Diagnosed major neurocognitive disorder (i.e., dementia)
  • Association of SCD or MCI with delirium
  • Diagnosed cardiometabolic disease (Uncontrolled hypertension (systolic blood pressure >160 mm Hg, and/or diastolic blood pressure >100 mm Hg, Type 2 diabetes)
  • Substance use disorder
  • History of heart attack or stroke requiring hospitalization in the past 3 years
  • MRI contraindications, including implanted medical devices
  • Experiencing residual fatigue, brain fog, or tiredness post-acute illness (i.e., long-COVID)
  • Severe literacy, visual, hearing, and/or speech impairment that would make participation in the study difficult or impossible
  • Individuals who are not fluent in Swiss German or German

Treatment and study plan

Oral ketone monoester (KME)

Dietary Supplement

The oral ketone monoester supplement should increase the global CBF and improve resting-state connectivity in the DMN in adults with SCD or MCI. The participants will take one dose of the supplement followed by measurement, to figure out if there are any noticeable changes.

Primary outcomes

  1. Functional connectivity of the DMN

    Time frame: 90 minutes

    Functional connectivity of the default mode network (DMN) is measured via functional MRI. Changes in BOLD signal in each region are determined by independent component analysis and then functional connectivity is measured as a Pearson correlation (r) between the neural regions comprising the DMN and transformed into a z score.

Secondary outcomes

  1. Cerebral blood flow

    Time frame: 90 minutes

    Sum of blood flow in the internal carotid and vertebral arteries via phase contrast MRI in ml/min.

Other outcomes

  1. Plasma β-OHB

    Time frame: 90 minutes

    Plasma β-OHB will be measured (in millimolar, mM) via finger prick at set intervals before and after supplement ingestion using a handheld commercial analyzer (FreeStyle Libre, Abbott).

  2. Arterial blood pressure

    Time frame: 90 minutes

    Automated blood pressure cuff measurement of brachial artery pressure in mmHg.

  3. Heart Rate

    Time frame: 90 minutes

    Automated blood pressure cuff measurement of heart rate in bpm.

Sponsors and collaborators

Lead sponsor

University Department of Geriatric Medicine FELIX PLATTER

Other

Collaborators

  • McMaster University

Registry information

Official study title

The Impact of Acute Oral Ketone Monoester Supplementation on Resting-state Brain Connectivity in Adults With Cognitive Decline

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 8, 2025
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.